While Collagen XXIII expression has already been suggested as potential biomarker for NSCLC, APCDD1L-AS1 expression is of prognostic value in squamous cell carcinoma and NTRK2 has recently been reported as therapeutic target in combination with tyrosine kinase inhibitors in this tumor entity29–31. The gene discussed is APCDD1L; the disease is squamous cell carcinoma.